You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameLoxapine
Accession NumberDB00408  (APRD00574)
TypeSmall Molecule
GroupsApproved
DescriptionAn antipsychotic agent used in schizophrenia. [PubChem]
Structure
Thumb
Synonyms
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine
Cloxazepine
Loxapina
Loxapine
Loxapinum
oxilapine
External Identifiers
  • AZ-004
  • BRN 0626753
  • CL 62362
  • CL 71563
  • HF 3170
  • LW 3170
  • S 805
  • SUM 3170
  • UNII-376MYL4MAL
  • UNII-LER583670J
  • UNII-X59SG0MRYU
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Adasuveaerosol, powder10 mg/1respiratory (inhalation)Teva Select Brands2014-01-22Not applicableUs
AdasuveInhalation powder, pre-dispensed4.5 mgInhalation useFerrer Internacional S.A.2013-02-20Not applicableEu
AdasuveInhalation powder, pre-dispensed9.1 mgInhalation useFerrer Internacional S.A.2013-02-20Not applicableEu
AdasuveInhalation powder, pre-dispensed4.5 mgInhalation useFerrer Internacional S.A.2013-02-20Not applicableEu
AdasuveInhalation powder, pre-dispensed9.1 mgInhalation useFerrer Internacional S.A.2013-02-20Not applicableEu
Dom-loxapine Tablets 10mgtablet10 mgoralDominion Pharmacal1999-09-15Not applicableCanada
Dom-loxapine Tablets 25mgtablet25 mgoralDominion Pharmacal1999-09-15Not applicableCanada
Dom-loxapine Tablets 50mgtablet50 mgoralDominion Pharmacal1999-09-15Not applicableCanada
Dom-loxapine Tablets 5mgtablet5 mgoralDominion Pharmacal1999-09-15Not applicableCanada
Loxapac - Tab 10mgtablet10 mgoralWyeth Ayerst Canada Inc.1997-09-242002-02-06Canada
Loxapac - Tab 50mgtablet50 mgoralWyeth Ayerst Canada Inc.1997-02-042001-05-22Canada
Loxapac - Tab 5mgtablet5 mgoralWyeth Ayerst Canada Inc.1997-02-042002-07-31Canada
Loxapac Imliquid50 mgintramuscularSandoz Canada Incorporated1997-06-13Not applicableCanada
Loxapac Inj 50mg/mlliquid50 mgintramuscularLederle Cyanamid Canada Inc.1980-12-311997-08-14Canada
Loxapac Oral Concentrate-liq 25mg/mlliquid25 mgoralWyeth Ayerst Canada Inc.1996-11-152001-09-19Canada
Loxapac Orl Conc 25mg/mlliquid25 mgoralLederle Cyanamid Canada Inc.1976-12-311997-08-14Canada
Loxapac Tab 10mgtablet13.6 mgoralLederle Cyanamid Canada Inc.1975-12-311999-04-12Canada
Loxapac Tab 25mgtablet34 mgoralLederle Cyanamid Canada Inc.1975-12-311997-08-14Canada
Loxapac Tab 50mgtablet68 mgoralLederle Cyanamid Canada Inc.1976-12-311997-08-14Canada
Loxapac Tab 5mgtablet6.8 mgoralLederle Cyanamid Canada Inc.1976-12-311997-08-14Canada
Loxapac Tablets - 25 mgtablet25 mgoralWyeth Ayerst Canada Inc.1997-06-132002-03-19Canada
Loxapine Hydrochloride Im Injection 50mg/mlliquid50 mgintramuscularWy Pharma Inc.Not applicableNot applicableCanada
Loxapine Hydrochloride Oral Concentrate 25mg/mlliquid25 mgoralWy Pharma Inc.Not applicableNot applicableCanada
Loxapine Succinate Tablets 10mgtablet10 mgoralWy Pharma Inc.Not applicableNot applicableCanada
Loxapine Succinate Tablets 25mgtablet25 mgoralWy Pharma Inc.Not applicableNot applicableCanada
Loxapine Succinate Tablets 5 mgtablet5 mgoralWy Pharma Inc.Not applicableNot applicableCanada
Loxapine Succinate Tablets 50mgtablet50 mgoralWy Pharma Inc.Not applicableNot applicableCanada
Loxapine-10tablet10 mgoralPro Doc Limitee1998-09-012010-07-13Canada
Loxapine-25tablet25 mgoralPro Doc Limitee1998-09-012010-07-13Canada
Loxapine-5tablet5 mgoralPro Doc Limitee1998-09-012010-07-13Canada
Loxapine-50tablet50 mgoralPro Doc Limitee1998-09-012010-07-13Canada
Nu-loxapinetablet10 mgoralNu Pharm Inc1998-07-022012-09-04Canada
Nu-loxapinetablet25 mgoralNu Pharm Inc1998-07-062012-09-04Canada
Nu-loxapinetablet50 mgoralNu Pharm Inc1998-07-132012-09-04Canada
Nu-loxapinetablet5 mgoralNu Pharm Inc1998-07-022012-09-04Canada
PHL-loxapinetablet10 mgoralPharmel Inc1998-02-16Not applicableCanada
PHL-loxapinetablet25 mgoralPharmel Inc1998-02-16Not applicableCanada
PHL-loxapinetablet2.5 mgoralPharmel Inc2004-07-22Not applicableCanada
PHL-loxapinetablet50 mgoralPharmel Inc1998-02-16Not applicableCanada
PHL-loxapinesolution25 mgoralPharmel Inc2004-07-22Not applicableCanada
PHL-loxapinetablet5 mgoralPharmel Inc1998-02-16Not applicableCanada
Xylactablet2.5 mgoralPendopharm Division Of De Pharmascience Inc2000-10-05Not applicableCanada
Xylactablet25 mgoralPendopharm Division Of De Pharmascience Inc1997-07-08Not applicableCanada
Xylactablet50 mgoralPendopharm Division Of De Pharmascience Inc1998-04-16Not applicableCanada
Xylactablet5 mgoralPendopharm Division Of De Pharmascience Inc1997-06-13Not applicableCanada
Xylacsolution25 mgoralPendopharm Division Of De Pharmascience Inc1998-12-03Not applicableCanada
Xylactablet10 mgoralPendopharm Division Of De Pharmascience Inc1998-04-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-loxapinetablet50 mgoralApotex Inc1998-03-30Not applicableCanada
Apo-loxapinetablet5 mgoralApotex Inc1998-03-30Not applicableCanada
Apo-loxapinetablet10 mgoralApotex Inc1998-03-30Not applicableCanada
Apo-loxapinetablet25 mgoralApotex Inc1998-03-30Not applicableCanada
Loxapinecapsule50 mg/1oralLannett Company, Inc.2011-09-26Not applicableUs
Loxapinecapsule5 mg/1oralCarilion Materials Management1988-06-15Not applicableUs
Loxapinecapsule10 mg/1oralMylan Institutional Inc.2004-12-15Not applicableUs
Loxapinecapsule5 mg/1oralMylan Pharmaceuticals Inc.2004-11-03Not applicableUs
Loxapinecapsule5 mg/1oralClinical Solutions Wholesale1988-06-15Not applicableUs
Loxapinetablet50 mg/1oralMarlex Pharmaceuticals Inc2014-10-01Not applicableUs
Loxapinecapsule50 mg/1oralEpic Pharma, LLC2015-01-02Not applicableUs
Loxapinecapsule50 mg/1oralWatson Laboratories, Inc.1988-06-15Not applicableUs
Loxapinecapsule10 mg/1oralAmerican Health Packaging2013-06-24Not applicableUs
Loxapinecapsule5 mg/1oralLannett Company, Inc.2011-09-26Not applicableUs
Loxapinecapsule5 mg/1oralWatson Laboratories, Inc.1988-06-15Not applicableUs
Loxapinecapsule25 mg/1oralMylan Institutional Inc.2004-12-15Not applicableUs
Loxapinecapsule10 mg/1oralMylan Pharmaceuticals Inc.2004-11-03Not applicableUs
Loxapinecapsule10 mg/1oralClinical Solutions Wholesale1988-06-15Not applicableUs
Loxapinetablet5 mg/1oralMarlex Pharmaceuticals Inc2014-10-01Not applicableUs
Loxapinecapsule5 mg/1oralEpic Pharma, LLC2015-01-02Not applicableUs
Loxapinecapsule10 mg/1oralLannett Company, Inc.2011-09-26Not applicableUs
Loxapinecapsule25 mg/1oralAmerican Health Packaging2013-06-24Not applicableUs
Loxapinecapsule50 mg/1oralMylan Institutional Inc.2004-12-15Not applicableUs
Loxapinecapsule10 mg/1oralWatson Laboratories, Inc.1988-06-15Not applicableUs
Loxapinecapsule25 mg/1oralMylan Pharmaceuticals Inc.2004-11-03Not applicableUs
Loxapinecapsule25 mg/1oralClinical Solutions Wholesale1988-06-15Not applicableUs
Loxapinecapsule10 mg/1oralEpic Pharma, LLC2015-01-02Not applicableUs
Loxapinetablet10 mg/1oralMarlex Pharmaceuticals Inc2014-10-01Not applicableUs
Loxapinecapsule25 mg/1oralLannett Company, Inc.2011-09-26Not applicableUs
Loxapinecapsule50 mg/1oralAmerican Health Packaging2013-06-24Not applicableUs
Loxapinecapsule10 mg/1oralREMEDYREPACK INC.2014-05-21Not applicableUs
Loxapinecapsule25 mg/1oralWatson Laboratories, Inc.1988-06-15Not applicableUs
Loxapinecapsule50 mg/1oralMylan Pharmaceuticals Inc.2004-11-03Not applicableUs
Loxapinecapsule50 mg/1oralClinical Solutions Wholesale1988-06-15Not applicableUs
Loxapinecapsule25 mg/1oralEpic Pharma, LLC2015-01-02Not applicableUs
Loxapinetablet25 mg/1oralMarlex Pharmaceuticals Inc2014-10-01Not applicableUs
Loxapine Succinatecapsule25 mg/1oralREMEDYREPACK INC.2011-08-15Not applicableUs
Loxapine Succinatecapsule5 mg/1oralREMEDYREPACK INC.2010-11-30Not applicableUs
Loxapine Succinatecapsule5 mg/1oralREMEDYREPACK INC.2011-09-15Not applicableUs
Loxapine Succinatecapsule10 mg/1oralREMEDYREPACK INC.2010-12-08Not applicableUs
Loxapine Succinatecapsule50 mg/1oralREMEDYREPACK INC.2011-09-15Not applicableUs
Loxapine Succinatecapsule50 mg/1oralREMEDYREPACK INC.2011-04-26Not applicableUs
Loxitanecapsule5 mg/1oralWatson Pharma, Inc.1988-06-15Not applicableUs
Loxitanecapsule10 mg/1oralWatson Pharma, Inc.1988-06-15Not applicableUs
Loxitanecapsule25 mg/1oralWatson Pharma, Inc.1988-06-15Not applicableUs
Loxitanecapsule50 mg/1oralWatson Pharma, Inc.1988-06-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CloxazepineNot Available
LopacNewai Chem
LosagenPatron
LoxapacWyeth
RosupSwiss Pharm
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Loxapine hydrochloride
ThumbNot applicableDBSALT001429
Loxapine succinate
ThumbNot applicableDBSALT001194
Categories
UNIILER583670J
CAS number1977-10-2
WeightAverage: 327.808
Monoisotopic: 327.11383992
Chemical FormulaC18H18ClN3O
InChI KeyInChIKey=XJGVXQDUIWGIRW-UHFFFAOYSA-N
InChI
InChI=1S/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3
IUPAC Name
13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene
SMILES
CN1CCN(CC1)C1=NC2=CC=CC=C2OC2=C1C=C(Cl)C=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzoxazepines. These are compounds containing a dibenzoxazepine moiety, which consists of two benzene connected by an oxazepine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxazepines
Sub ClassDibenzoxazepines
Direct ParentDibenzoxazepines
Alternative Parents
Substituents
  • Dibenzoxazepine
  • Diaryl ether
  • N-alkylpiperazine
  • N-methylpiperazine
  • Chlorobenzene
  • Imidolactam
  • Benzenoid
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Ether
  • Carboxylic acid amidine
  • Amidine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of the manifestations of psychotic disorders such as schizophrenia
PharmacodynamicsLoxapine, a dibenzoxazepine compound, represents a subclass of tricyclic antipsychotic agents, chemically distinct from the thioxanthenes, butyrophenones, and phenothiazines. Pharmacologically, Loxapine is a tranquilizer for which the exact mode of action has not been established, however, it is believed that by antagonising dopamine and serotonin receptors, there is a marked cortical inhibition which can manifest as tranquilization and suppression of aggression.
Mechanism of actionLoxapine is a dopamine antagonist, and also a serotonin 5-HT2 blocker. The exact mode of action of Loxapine has not been established, however changes in the level of excitability of subcortical inhibitory areas have been observed in several animal species in association with such manifestations of tranquilization as calming effects and suppression of aggressive behavior.
Related Articles
AbsorptionSystemic bioavailability of the parent drug was only about one third that after an equivalent intramuscular dose (25 mg base) in male volunteers
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic

Route of eliminationMetabolites are excreted in the urine in the form of conjugates and in the feces unconjugated.
Half lifeOral-4 hours
ClearanceNot Available
ToxicityLD50=65 mg/kg (Orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9944
Blood Brain Barrier+0.9801
Caco-2 permeable+0.5531
P-glycoprotein substrateSubstrate0.8545
P-glycoprotein inhibitor IInhibitor0.8525
P-glycoprotein inhibitor IIInhibitor0.8388
Renal organic cation transporterInhibitor0.7084
CYP450 2C9 substrateNon-substrate0.7331
CYP450 2D6 substrateSubstrate0.7155
CYP450 3A4 substrateSubstrate0.6309
CYP450 1A2 substrateInhibitor0.8159
CYP450 2C9 inhibitorNon-inhibitor0.8755
CYP450 2D6 inhibitorInhibitor0.7543
CYP450 2C19 inhibitorNon-inhibitor0.6217
CYP450 3A4 inhibitorNon-inhibitor0.9393
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6968
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8743
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.3057 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5701
hERG inhibition (predictor II)Inhibitor0.6141
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Watson laboratories inc
  • Actavis totowa llc
  • Mylan pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Aerosol, powderrespiratory (inhalation)10 mg/1
Inhalation powder, pre-dispensedInhalation use4.5 mg
Inhalation powder, pre-dispensedInhalation use9.1 mg
Liquidintramuscular50 mg
Liquidoral25 mg
Tabletoral13.6 mg
Tabletoral34 mg
Tabletoral68 mg
Tabletoral6.8 mg
Capsuleoral10 mg/1
Capsuleoral25 mg/1
Capsuleoral5 mg/1
Capsuleoral50 mg/1
Tabletoral10 mg/1
Tabletoral25 mg/1
Tabletoral5 mg/1
Tabletoral50 mg/1
Solutionoral25 mg
Tabletoral10 mg
Tabletoral2.5 mg
Tabletoral25 mg
Tabletoral5 mg
Tabletoral50 mg
Prices
Unit descriptionCostUnit
Loxapac 50 mg/ml7.05USD ml
Loxitane 50 mg capsule4.04USD capsule
Loxitane 25 mg capsule3.09USD capsule
Loxapine 50 mg capsule2.57USD capsule
Loxitane 10 mg capsule2.04USD capsule
Loxapine 25 mg capsule1.92USD capsule
Loxitane 5 mg capsule1.58USD capsule
Loxapine 10 mg capsule1.27USD capsule
Loxapine Succinate 5 mg capsule1.03USD capsule
Loxapine 5 mg capsule0.99USD capsule
Pms-Loxapine 50 mg Tablet0.54USD tablet
Pms-Loxapine 25 mg Tablet0.41USD tablet
Pms-Loxapine 10 mg Tablet0.26USD tablet
Pms-Loxapine 5 mg Tablet0.16USD tablet
Pms-Loxapine 2.5 mg Tablet0.08USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6716416 No2002-05-202022-05-20Us
US7052679 No2001-10-262021-10-26Us
US7078020 No2001-10-262021-10-26Us
US7090830 No2001-10-262021-10-26Us
US7458374 No2004-08-182024-08-18Us
US7537009 No2004-10-282024-10-28Us
US7585493 No2001-10-262021-10-26Us
US7601337 No2001-10-262021-10-26Us
US8074644 No2002-07-252022-07-25Us
US8173107 No2001-10-262021-10-26Us
US8235037 No2001-10-262021-10-26Us
US8387612 No2006-10-232026-10-23Us
US8955512 No2001-10-262021-10-26Us
US8991387 No2004-05-212024-05-21Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point109-111 °CU.S. Patents 3,412,193; 3,546,226.
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.103 mg/mLALOGPS
logP3.18ALOGPS
logP3.46ChemAxon
logS-3.5ALOGPS
pKa (Strongest Basic)7.18ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area28.07 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity95.11 m3·mol-1ChemAxon
Polarizability34.99 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4l-7590000000-118f30ca0699bf2b3d2eView in MoNA
References
Synthesis Reference

U.S. Patents 3,412,193; 3,546,226.

US3412193
General References
  1. Glazer WM: Does loxapine have "atypical" properties? Clinical evidence. J Clin Psychiatry. 1999;60 Suppl 10:42-6. [PubMed:10340686 ]
  2. Cheung SW, Tang SW, Remington G: Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography. J Chromatogr. 1991 Mar 8;564(1):213-21. [PubMed:1860915 ]
External Links
ATC CodesN05AH01
AHFS Codes
  • 28:16.08.92
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineLoxapine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineLoxapine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Loxapine is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Loxapine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Loxapine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Loxapine is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Loxapine is combined with Alfentanil.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Loxapine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Loxapine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Loxapine.
AmisulprideThe risk or severity of adverse effects can be increased when Loxapine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Loxapine.
AmobarbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Loxapine is combined with Amperozide.
AmphetamineLoxapine may decrease the stimulatory activities of Amphetamine.
AripiprazoleThe risk or severity of adverse effects can be increased when Loxapine is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Azaperone.
AzelastineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Loxapine.
BaclofenThe risk or severity of adverse effects can be increased when Loxapine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Benzocaine.
BenzphetamineLoxapine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Loxapine is combined with Benzyl alcohol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Loxapine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
BrimonidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Loxapine.
BrompheniramineThe risk or severity of adverse effects can be increased when Loxapine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Loxapine is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Loxapine.
BuprenorphineThe risk or severity of adverse effects can be increased when Loxapine is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Loxapine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Loxapine.
ButacaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Loxapine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Loxapine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Loxapine is combined with Butorphanol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Loxapine.
CarbamazepineThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Loxapine.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Loxapine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Loxapine is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Loxapine is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Loxapine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorphenamine.
ChlorphentermineLoxapine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Loxapine is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Loxapine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Loxapine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Loxapine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Loxapine is combined with Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Loxapine.
CocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Loxapine.
CyclizineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Loxapine.
CyproheptadineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Loxapine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Loxapine.
DapoxetineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Loxapine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Loxapine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Loxapine.
DesloratadineThe risk or severity of adverse effects can be increased when Loxapine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Loxapine.
DetomidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dexmedetomidine.
DextroamphetamineLoxapine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Loxapine.
DextromoramideThe risk or severity of adverse effects can be increased when Loxapine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Loxapine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Loxapine is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Loxapine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dihydromorphine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Loxapine is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Loxapine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Loxapine is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Loxapine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Loxapine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
DoxylamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Loxapine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
DroperidolThe risk or severity of adverse effects can be increased when Loxapine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Loxapine is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Loxapine.
DyclonineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Loxapine is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Loxapine is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Loxapine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Loxapine.
EntacaponeThe risk or severity of adverse effects can be increased when Loxapine is combined with Entacapone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Loxapine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Loxapine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Loxapine.
EscitalopramThe risk or severity of adverse effects can be increased when Loxapine is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Loxapine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Loxapine.
EthanolLoxapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Loxapine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Loxapine.
EthosuximideThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Loxapine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Loxapine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Loxapine.
EtoperidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Loxapine is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Loxapine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Loxapine.
FexofenadineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Loxapine is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Loxapine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Loxapine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Loxapine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Loxapine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Loxapine.
GabapentinThe risk or severity of adverse effects can be increased when Loxapine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Loxapine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Loxapine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Loxapine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Loxapine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Loxapine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Loxapine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Loxapine is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Loxapine.
Hydroxyamphetamine hydrobromideLoxapine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
HydroxyzineThe risk or severity of adverse effects can be increased when Loxapine is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Loxapine.
IndalpineThe risk or severity of adverse effects can be increased when Loxapine is combined with Indalpine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Loxapine.
IsofluraneThe risk or severity of adverse effects can be increased when Loxapine is combined with Isoflurane.
KetamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Loxapine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Loxapine is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Loxapine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Loxapine is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Loxapine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Loxapine is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Loxapine is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Loxapine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Loxapine.
LisdexamfetamineLoxapine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Loxapine.
LithiumThe risk or severity of adverse effects can be increased when Loxapine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Loxapine is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Loxapine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Lorazepam.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Loxapine is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Loxapine is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Loxapine.
MeclizineThe risk or severity of adverse effects can be increased when Loxapine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Loxapine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Melperone.
MephentermineLoxapine may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Loxapine.
MequitazineLoxapine may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Loxapine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Loxapine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Loxapine is combined with Methadyl Acetate.
MethamphetamineLoxapine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Loxapine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Loxapine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Loxapine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Loxapine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Methylphenobarbital.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Loxapine.
MetyrosineLoxapine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Loxapine.
MidazolamThe risk or severity of adverse effects can be increased when Loxapine is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Loxapine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
MirtazapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Loxapine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Loxapine.
MolindoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Loxapine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Loxapine.
NabiloneThe risk or severity of adverse effects can be increased when Loxapine is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Loxapine is combined with Nalbuphine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Loxapine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Loxapine.
NitrazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Loxapine is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Loxapine.
OlanzapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Loxapine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Loxapine is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Loxapine is combined with Opium.
OrphenadrineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Loxapine.
OsanetantThe risk or severity of adverse effects can be increased when Loxapine is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Paliperidone.
ParaldehydeLoxapine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Loxapine.
ParoxetineThe risk or severity of adverse effects can be increased when Loxapine is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Loxapine.
PerampanelThe risk or severity of adverse effects can be increased when Loxapine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Loxapine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Loxapine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Loxapine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Loxapine is combined with Phenoxyethanol.
PhentermineLoxapine may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Loxapine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Loxapine is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Loxapine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Loxapine is combined with Pomalidomide.
PramipexoleLoxapine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Loxapine.
PrilocaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Loxapine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Prochlorperazine.
PromazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Loxapine.
ProparacaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Loxapine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Loxapine.
PSD502The risk or severity of adverse effects can be increased when Loxapine is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Quetiapine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Loxapine.
RamelteonThe risk or severity of adverse effects can be increased when Loxapine is combined with Ramelteon.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Loxapine.
RemifentanilThe risk or severity of adverse effects can be increased when Loxapine is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Loxapine is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Loxapine.
RisperidoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Risperidone.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Loxapine.
RomifidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Romifidine.
RopiniroleLoxapine may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Loxapine.
RotigotineLoxapine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Loxapine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Loxapine is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Loxapine is combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Loxapine.
SertindoleThe risk or severity of adverse effects can be increased when Loxapine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Loxapine is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Loxapine is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Loxapine is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Loxapine is combined with Sufentanil.
SulpirideThe risk or severity of adverse effects can be increased when Loxapine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Loxapine.
SuvorexantThe risk or severity of adverse effects can be increased when Loxapine is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Loxapine.
TasimelteonThe risk or severity of adverse effects can be increased when Loxapine is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Loxapine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Loxapine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Loxapine.
TetracaineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Loxapine is combined with Tetrodotoxin.
ThalidomideLoxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Loxapine.
ThiamylalThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Loxapine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Loxapine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Loxapine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Loxapine.
TrazodoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Loxapine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Loxapine.
TriprolidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Loxapine.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Loxapine.
VigabatrinThe risk or severity of adverse effects can be increased when Loxapine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Loxapine is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Loxapine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Loxapine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Loxapine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Loxapine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Loxapine.
ZolazepamThe risk or severity of adverse effects can be increased when Loxapine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Loxapine.
ZolpidemThe risk or severity of adverse effects can be increased when Loxapine is combined with Zolpidem.
ZonisamideThe risk or severity of adverse effects can be increased when Loxapine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Loxapine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Loxapine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Loxapine is combined with Zuclopenthixol.
Food Interactions
  • Take with food to reduce irritation. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Lee T, Tang SW: Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res. 1984 Aug;12(4):277-85. [PubMed:6239298 ]
  2. Hjerde E, Dahl SG, Sylte I: Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor. Eur J Med Chem. 2005 Feb;40(2):185-94. [PubMed:15694653 ]
  3. Kalkman HO, Neumann V, Nozulak J, Tricklebank MD: Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat. Eur J Pharmacol. 1998 Feb 19;343(2-3):201-7. [PubMed:9570468 ]
  4. Froimowitz M, Cody V: Biologically active conformers of phenothiazines and thioxanthenes. Further evidence for a ligand model of dopamine D2 receptor antagonists. J Med Chem. 1993 Jul 23;36(15):2219-27. [PubMed:8101879 ]
  5. Froimowitz M, Cody V: The incorporation of butyrophenones and related compounds into a pharmacophore for dopamine D2 antagonists. Drug Des Discov. 1997 Aug;15(2):63-81. [PubMed:9342550 ]
  6. Lang AE, Sandor P, Duff J: Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45. [PubMed:8665533 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Li Z, Ichikawa J, Meltzer HY: A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl). 2003 May;167(3):315-23. Epub 2003 Mar 28. [PubMed:12664192 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Herrick-Davis K, Grinde E, Teitler M: Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther. 2000 Oct;295(1):226-32. [PubMed:10991983 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
Gene Name:
HTR1E
Uniprot ID:
P28566
Molecular Weight:
41681.57 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins.
Gene Name:
HTR5A
Uniprot ID:
P47898
Molecular Weight:
40254.69 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through...
Gene Name:
HTR6
Uniprot ID:
P50406
Molecular Weight:
46953.625 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD5
Uniprot ID:
P21918
Molecular Weight:
52950.5 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Histamine receptor activity
Specific Function:
The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).
Gene Name:
HRH4
Uniprot ID:
Q9H3N8
Molecular Weight:
44495.375 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. PDSP Ki Database [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2016 02:16